[1]
Onishchenko AL, Isakov IN, Kolbasko AV, Makogon SI. [Initial combination therapy for primary open-angle glaucoma]. Vestnik oftalmologii. 2019:135(2):32-38. doi: 10.17116/oftalma201913502132. Epub
[PubMed PMID: 31215532]
[2]
Buckley MM, Goa KL, Clissold SP. Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs. 1990 Jul:40(1):75-90
[PubMed PMID: 2202584]
[4]
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014 May 14:311(18):1901-11. doi: 10.1001/jama.2014.3192. Epub
[PubMed PMID: 24825645]
[5]
Chidlow G, Melena J, Osborne NN. Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists. British journal of pharmacology. 2000 Jun:130(4):759-66
[PubMed PMID: 10864881]
[6]
Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008 Jul:115(7):1117-1122.e1
[PubMed PMID: 18082886]
Level 1 (high-level) evidence
[7]
Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, Li T, Mansberger SL, American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel. Primary Open-Angle Glaucoma Preferred Practice Pattern®. Ophthalmology. 2021 Jan:128(1):P71-P150. doi: 10.1016/j.ophtha.2020.10.022. Epub 2020 Nov 12
[PubMed PMID: 34933745]
[8]
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun:71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13
[PubMed PMID: 29133356]
Level 1 (high-level) evidence
[9]
Writing Committee Members, Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, Dixon DL, Fearon WF, Hess B, Johnson HM, Kazi DS, Kolte D, Kumbhani DJ, LoFaso J, Mahtta D, Mark DB, Minissian M, Navar AM, Patel AR, Piano MR, Rodriguez F, Talbot AW, Taqueti VR, Thomas RJ, van Diepen S, Wiggins B, Williams MS. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2023 Aug 29:82(9):833-955. doi: 10.1016/j.jacc.2023.04.003. Epub 2023 Jul 20
[PubMed PMID: 37480922]
Level 1 (high-level) evidence
[10]
Pal PK. Guidelines for management of essential tremor. Annals of Indian Academy of Neurology. 2011 Jul:14(Suppl 1):S25-8. doi: 10.4103/0972-2327.83097. Epub
[PubMed PMID: 21847325]
[11]
Yen CF, Hsu CK, Lu CW. Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors. Journal of the American Academy of Dermatology. 2018 Jun:78(6):e143-e144. doi: 10.1016/j.jaad.2018.01.015. Epub 2018 Jan 12
[PubMed PMID: 29339238]
[12]
Dong Y, Ishikawa H, Wu Y, Shimizu K, Goseki T, Yoshitomi T. Effect and mechanism of betaxolol and timolol on vascular relaxation in isolated rabbit ciliary artery. Japanese journal of ophthalmology. 2006 Nov-Dec:50(6):504-508. doi: 10.1007/s10384-006-0377-2. Epub 2006 Dec 18
[PubMed PMID: 17180523]
[13]
Lezama-Martínez D, Valencia-Hernández I, Flores-Monroy J, Martínez-Aguilar L. Combination of β Adrenergic Receptor Block and Renin-Angiotensin System Inhibition Diminished the Angiotensin II-Induced Vasoconstriction and Increased Bradykinin-Induced Vasodilation in Hypertension. Dose-response : a publication of International Hormesis Society. 2017 Oct-Dec:15(4):1559325817737932. doi: 10.1177/1559325817737932. Epub 2017 Nov 12
[PubMed PMID: 29162996]
[14]
Holló G, Whitson JT, Faulkner R, McCue B, Curtis M, Wieland H, Chastain J, Sanders M, DeSantis L, Przydryga J, Dahlin DC. Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration. Investigative ophthalmology & visual science. 2006 Jan:47(1):235-40
[PubMed PMID: 16384968]
[15]
Fayyaz A, Ranta VP, Toropainen E, Vellonen KS, Ricci GD, Reinisalo M, Heikkinen EM, Gardner I, Urtti A, Jamei M, Del Amo EM. Ocular Intracameral Pharmacokinetics for a Cocktail of Timolol, Betaxolol, and Atenolol in Rabbits. Molecular pharmaceutics. 2020 Feb 3:17(2):588-594. doi: 10.1021/acs.molpharmaceut.9b01024. Epub 2020 Jan 9
[PubMed PMID: 31794668]
[16]
Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions. International journal of molecular sciences. 2021 Dec 10:22(24):. doi: 10.3390/ijms222413302. Epub 2021 Dec 10
[PubMed PMID: 34948113]
[17]
Zhu Q, Cheng H, Huo Y, Mao S. Sustained ophthalmic delivery of highly soluble drug using pH-triggered inner layer-embedded contact lens. International journal of pharmaceutics. 2018 Jun 10:544(1):100-111. doi: 10.1016/j.ijpharm.2018.04.004. Epub 2018 Apr 5
[PubMed PMID: 29627356]
[18]
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstetrics and gynecology. 2019 Jan:133(1):e26-e50. doi: 10.1097/AOG.0000000000003020. Epub
[PubMed PMID: 30575676]
[20]
Pozzi R. [True and presumed contraindications of beta blockers. Peripheral vascular disease, diabetes mellitus, chronic bronchopneumopathy]. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology. 2000 Aug:1(8):1031-7
[PubMed PMID: 10993010]
[21]
Siddiqui M, Bhatt H, Judd EK, Oparil S, Calhoun DA. Reserpine Substantially Lowers Blood Pressure in Patients With Refractory Hypertension: A Proof-of-Concept Study. American journal of hypertension. 2020 Aug 4:33(8):741-747. doi: 10.1093/ajh/hpaa042. Epub
[PubMed PMID: 32179903]
[22]
Handler J. Adverse effects using combined rate-slowing antihypertensive agents. Journal of clinical hypertension (Greenwich, Conn.). 2011 Jul:13(7):529-32. doi: 10.1111/j.1751-7176.2011.00486.x. Epub 2011 Jun 20
[PubMed PMID: 21762367]
[23]
Lu HT, Kam J, Nordin RB, Khelae SK, Wang JM, Choy CN, Lee CY. Beta-blocker use and risk of symptomatic bradyarrhythmias: a hospital-based case-control study. Journal of geriatric cardiology : JGC. 2016 Sep:13(9):749-759
[PubMed PMID: 27899939]
Level 2 (mid-level) evidence
[24]
Haase G, Pietzsch M, Fähnrich A, Voss W, Riethling AK. Results of a systematic adverse drug reaction (ADR)-screening concerning bradycardia caused by drug interactions in departments of internal medicine in Rostock. International journal of clinical pharmacology and therapeutics. 2002 Mar:40(3):116-9
[PubMed PMID: 11911600]
Level 1 (high-level) evidence
[25]
Maideen NMP, Rajkapoor B, Muthusamy S, Ramanathan S, Thangadurai SA, Sughir AA. A Review on Pharmacokinetic and Pharmacodynamic Drug Interactions of Adrenergic β-blockers with Clinically Relevant Drugs-An Overview. Current drug metabolism. 2021:22(9):672-682. doi: 10.2174/1389200222666210614112529. Epub
[PubMed PMID: 34182907]
Level 3 (low-level) evidence
[26]
Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC. 2016 May:149(3):139-52. doi: 10.1177/1715163516641136. Epub 2016 Apr 8
[PubMed PMID: 27212965]
[27]
Meng T, Ren X, Chen X, Yu J, Agrimi J, Paolocci N, Gao WD. Anesthetic Agents Isoflurane and Propofol Decrease Maximal Ca(2+)-Activated Force and Thus Contractility in the Failing Myocardium. The Journal of pharmacology and experimental therapeutics. 2019 Dec:371(3):615-623. doi: 10.1124/jpet.119.259556. Epub 2019 Sep 12
[PubMed PMID: 31515443]
[28]
Alves PB, Figueiredo AC, Codeço C, Regateiro FS, Gonçalo M. A closer look at allergic contact dermatitis caused by topical ophthalmic medications. Contact dermatitis. 2022 Oct:87(4):331-335. doi: 10.1111/cod.14174. Epub 2022 Jun 28
[PubMed PMID: 35715881]
[29]
Özcan KS, Güngör B, Osmonov D, Tekkeşin AI, Altay S, Ekmekçi A, Toprak E, Yildirim E, Çalik N, Alper AT, Gürkan K, Erdinler I. Management and outcome of topical beta-blocker-induced atrioventricular block. Cardiovascular journal of Africa. 2015 Nov-Dec:26(6):210-3. doi: 10.5830/CVJA-2015-030. Epub
[PubMed PMID: 26659434]
[30]
Teerlink JR, Alburikan K, Metra M, Rodgers JE. Acute decompensated heart failure update. Current cardiology reviews. 2015:11(1):53-62
[PubMed PMID: 24251454]
[31]
Khella SL, Kozart D. Unmasking and exacerbation of myasthenia gravis by ophthalmic solutions: betoxolol, tobramycin, and dexamethasone. A case report. Muscle & nerve. 1997 May:20(5):631
[PubMed PMID: 9140379]
Level 3 (low-level) evidence
[32]
Koracevic G, Micic S, Stojanovic M, Tomasevic M, Kostic T, Velickovic Radovanovic R, Lovic D, Djordjevic D, Randjelovic M, Koracevic M, Ristic Z. Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies. Hypertension research : official journal of the Japanese Society of Hypertension. 2020 Jul:43(7):591-596. doi: 10.1038/s41440-020-0449-6. Epub 2020 May 7
[PubMed PMID: 32382156]
[33]
London MJ, Hur K, Schwartz GG, Henderson WG. Association of perioperative β-blockade with mortality and cardiovascular morbidity following major noncardiac surgery. JAMA. 2013 Apr 24:309(16):1704-13. doi: 10.1001/jama.2013.4135. Epub
[PubMed PMID: 23613075]
[34]
Myklejord DJ. Undiagnosed pheochromocytoma: the anesthesiologist nightmare. Clinical medicine & research. 2004 Feb:2(1):59-62
[PubMed PMID: 15931336]
[35]
Garg MK, Kharb S, Brar KS, Gundgurthi A, Mittal R. Medical management of pheochromocytoma: Role of the endocrinologist. Indian journal of endocrinology and metabolism. 2011 Oct:15 Suppl 4(Suppl4):S329-36. doi: 10.4103/2230-8210.86976. Epub
[PubMed PMID: 22145136]
[36]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3:145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1
[PubMed PMID: 35363499]
Level 1 (high-level) evidence
[37]
Erkin EF, Celik P, Kayikçioğlu O, Deveci HM, Sakar A. Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 2006:220(5):332-7
[PubMed PMID: 16954712]
[38]
Anık A. Beta-blocker Rebound Phenomenon in an Adolescent with Graves’ Disease. Journal of clinical research in pediatric endocrinology. 2022 Dec 1:14(4):490-491. doi: 10.4274/jcrpe.galenos.2022.2022-6-2. Epub 2022 Jul 21
[PubMed PMID: 35859995]
[40]
Shepherd G. Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 2006 Oct 1:63(19):1828-35
[PubMed PMID: 16990629]
[41]
Lauterbach M. Clinical toxicology of beta-blocker overdose in adults. Basic & clinical pharmacology & toxicology. 2019 Aug:125(2):178-186. doi: 10.1111/bcpt.13231. Epub 2019 Apr 15
[PubMed PMID: 30916882]
[42]
Kerns W 2nd, Kline J, Ford MD. Beta-blocker and calcium channel blocker toxicity. Emergency medicine clinics of North America. 1994 May:12(2):365-90
[PubMed PMID: 7910555]
[43]
Bilbault P, Pynn S, Mathien C, Mazzucotelli JP, Schneider F, Jaeger A. Near-fatal betaxolol self-poisoning treated with percutaneous extracorporeal life support. European journal of emergency medicine : official journal of the European Society for Emergency Medicine. 2007 Apr:14(2):120-2
[PubMed PMID: 17496693]
[44]
Bott D, Subramanian A, Edgar D, Lawrenson JG, Campbell P. Barriers and enablers to medication adherence in glaucoma: A systematic review of modifiable factors using the Theoretical Domains Framework. Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists). 2024 Jan:44(1):96-114. doi: 10.1111/opo.13245. Epub 2023 Nov 20
[PubMed PMID: 37985237]
Level 1 (high-level) evidence